Compare Smith & Nephew plc (SNN) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs SYSCO Corporation — how do they compare? Smith & Nephew plc trades at $27.11 (market cap $11.10B), while SYSCO Corporation trades at $78.42 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 3.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and SYSCO Corporation for 77 Days on average.
| SNN | SYY | |
|---|---|---|
Market Cap | $11.10B | $38.47B |
Volume | 1,051,703 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $37.17 | $91.16 |
52-Week Low | $26.42 | $69.30 |
Typical Hold Time | 120 Days | 77 Days |
Enterprise Value | $14.13B | $51.65B |
Dividend Yield | 2.95% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
SYY trades at $78.31, up 1.98% today, with a neutral technical signal and mixed earnings history. The company reported revenue growth to $81.37B in 2025, though net income margin dipped to 2.08%. Recent news highlights a $500M AI efficiency program and a $1.5B senior notes offering, signaling strategic investments. Analyst consensus is bullish with a $85.75 price target, but the stock faces headwinds from high debt levels and competitive pressures.
The outlook for SYY is cautiously optimistic, supported by steady revenue growth and a strong analyst buy rating. Key opportunities include AI-driven cost savings and market expansion, while risks involve elevated leverage and margin compression. Investors should weigh the potential for earnings acceleration against macroeconomic sensitivity in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
